Form 4: Minerva Neurosciences CBO Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Chief Business Officer and General Counsel James Joseph O'Connor was granted 350,800 employee stock options in Minerva Neurosciences.
Summary
- James Joseph O'Connor, Chief Business Officer and General Counsel of Minerva Neurosciences, Inc. (NERV), was granted 350,800 employee stock options.
- The options have an exercise price of $6.97 per share.
- The grant date for these options is April 21, 2026.
- The options are set to expire on April 20, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which carries a neutral sentiment.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future shareholder dilution upon the exercise of these stock options.
Risks
- The value of the options is dependent on the future performance of NERV common stock.
- Vesting requirements may influence executive retention and long-term strategic focus.
Future Outlook
The options vest 25% on April 21, 2027, with the remaining balance vesting in equal quarterly installments over the subsequent three years.
Industry Context
StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to incentivize long-term development milestones and align leadership with clinical trial outcomes.
Comparison to Industry Standards
- The use of multi-year vesting schedules is consistent with standard corporate governance practices in the pharmaceutical and biotech industries to ensure executive retention.
- The grant size is typical for a C-level executive at a small-cap biotechnology firm.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of 25% of the options on April 21, 2027.
- Continued quarterly vesting of the remaining options through 2030.
Key Dates
| Date | Description |
|---|---|
| 04/21/2026 | Date of the stock option grant transaction. |
| 04/21/2027 | Initial 25% vesting date for the granted options. |
| 04/20/2036 | Expiration date of the granted stock options. |
Keywords
Minerva Neurosciences, NERV, Form 4, Insider Trading, Stock Options, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.